The Filing Desk

ProQR Therapeutics vs Sol-Gel Technologies

ProQR Therapeutics PRQR · Sol-Gel Technologies SLGL · Pharmaceuticals

ProQR Therapeutics reported revenue of €16 million in fiscal 2025, and Sol-Gel Technologies $19 million in fiscal 2025, in different currencies. ProQR Therapeutics' revenue fell 15.9% in its latest year, and Sol-Gel Technologies' grew 68.0%. ProQR Therapeutics had an operating margin of -273.1%, against -38.9% at Sol-Gel Technologies. Free cash flow was −€54 million at ProQR Therapeutics and $0 million at Sol-Gel Technologies.

Side by side

ProQR TherapeuticsSol-Gel Technologies
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue€16M$19M
Revenue growth−15.9%68.0%
Revenue growth a year, last 5 years—17.1%
Gross margin——
Operating margin−273.1%−38.9%
Net margin−265.2%−31.6%
Free cash flow−€54M$0M
Free cash flow margin−338.3%1.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks€0M$0M
Change in diluted share count22.4%0.0%
Last close$1.05$54.08
P/E at the last close——
Insider trades, last 12 months—bought $11.2 million, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
ProQR TherapeuticsSol-Gel Technologies
Operating margin
Percent of revenue
ProQR TherapeuticsSol-Gel Technologies
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
ProQR TherapeuticsSol-Gel Technologies

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ProQR Therapeutics and Sol-Gel Technologies pages.